VF
SIOX

Virtu Financial’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Virtu Financial’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,793
Closed -$73K – 2098
2018
Q3 		$73K Sell
3,793
-2,184
-37% -$39.7K ﹤0.01% 1251
2018
Q2 		$108K Buy
+5,977
New +$88.2K 0.01% 1634
2018
Q1 		– Sell
-2,686
Closed -$113K – 2805
2017
Q4 		$113K Buy
+2,686
New +$121K 0.01% 1875

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial's SIOX Position: Q4 2018 in Review

Virtu Financial sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 3,793 shares — an estimated $73K sold.

Virtu Financial first reported a position in SIOX in Q4 2017 and held it in 3 quarters. The position peaked at $113K in Q4 2017. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Virtu Financial reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Virtu Financial sold 3,793 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $73K.
  • Virtu Financial first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Virtu Financial's Sio Gene Therapies Inc. Common Stock position peaked at $113K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Virtu Financial's 13F filing for Q4 2018, filed 16 Jan 2019.